Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) EBIT: ₺-233.9 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IST:ANGEN Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve IST:ANGEN
58 GF Score
Price ₺10.19
GF Value ₺18.66
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve EBIT?

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve IST:ANGEN 58 EBIT is ₺-233.9 Mil as of Mar. 2026. GuruFocus rates IST:ANGEN with a GF Score™ of 58/100 and a GF Value™ of ₺18.66 (Possible Value Trap). The stock has 4 warning signs investors should review.

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₺-99.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₺-233.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's annualized ROC % for the quarter that ended in Mar. 2026 was -10.06%. Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -27.06%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -8.98%.


Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve  (IST:ANGEN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-226.124 * ( 1 - 0% )/( (2151.991 + 2344.032)/ 2 )
=-226.124/2248.0115
=-10.06 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2362.952 - 108.228 - ( 102.733 - max(0, 256.52 - 724.427+102.733))
=2151.991

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2602.188 - 129.436 - ( 128.72 - max(0, 326.878 - 756.079+128.72))
=2344.032

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-396.952/( ( (975.728 + max(438.492, 0)) + (1078.164 + max(441.807, 0)) )/ 2 )
=-396.952/( ( 1414.22 + 1519.971 )/ 2 )
=-396.952/1467.0955
=-27.06 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(190.218 + 340.552 + 67.365) - (108.228 + 0 + 51.415)
=438.492

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(183.763 + 292.072 + 127.278) - (129.436 + 0 + 31.87)
=441.807

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-233.885/2603.712
=-8.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve EBIT Related Terms


Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve EBIT Historical Data

* Premium members only.

The historical data trend for Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve EBIT Chart

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 464.33 49.31 -206.08 -216.60 -247.49

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -123.63 -69.52 -59.82 -5.31 -99.24

IST:ANGEN vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's EV-to-EBIT falls into.


IST:ANGEN
58GF Score
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve IST:ANGEN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺-233.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₺-233.9 Mil mean?
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) has a EBIT of ₺-233.9 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve.
Is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's EBIT too high?
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's current EBIT is ₺-233.9 Mil. Overall, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's EBIT compare to ABT and SYK?
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's EBIT of ₺-233.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve. Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's current EBIT is ₺-233.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve stock overvalued right now?
Based on GuruFocus' analysis, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) is currently considered Possible Value Trap. The stock's GF Value™ is ₺18.66, compared to a current price of ₺10.19 — trading 45.4% below its estimated fair value. The current EBIT is ₺-233.9 Mil. Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN), the current EBIT is ₺-233.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve stock appears to be undervalued. The current stock price of ₺10.19 is trading 45.4% below its estimated GF Value™ of ₺18.66. GuruFocus considers Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve to be Possible Value Trap.

Key valuation signals for IST:ANGEN:

  • EBIT: ₺-233.9 Mil
  • GF Value™: ₺18.66 vs. price of ₺10.19 (45.4% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the IST:ANGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Business Description

Address Egitim Mah. Kasap Ismail, Sk. No:10 D:23, Kadikoy, Istanbul, TUR, 34722
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve Ticaret AS is an international biotechnology company. It is engaged in designing, developing, and manufacturing Real-Time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments. It also manufactures NA Extraction kits, Microbiology kits, Genetic Disorders kits, Panel kits, Sequencing kits, Food Testing kits.
58GF Score

Get the complete analysis for IST:ANGEN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₺10.19
Price
₺18.66
GF Value